ArticleRisk management and healthcare policy2026
Development and Validation of a Predictive Screening Model for Congenital Heart Disease in High-Altitude Children.
Article in Risk management and healthcare policy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Purpose: Current congenital heart disease (CHD) screening protocols adopt plain-standard criteria, yet they predispose to missed diagnoses and misdiagnoses in high-altitude hypoxic environments. This study aimed to develop and validate a predictive model for early CHD screening in plateau-region school-aged children and to evaluate the cost-effectiveness of different screening strategies. Methods: Cross-sectional data from 7315 school-age children undergoing initial school screening in high-altitude areas were analyzed using R 4.2.0 and SPSS 26.0. A logistic regression model predicting CHD detection rate was built via stepwise selection. Model performance was assessed through decision curve analysis (DCA), calibration curves, and ROC analysis. Variable importance was visualized via random forest plots. Cost-effectiveness of three screening strategies was evaluated using a Markov model. Results: Logistic regression model identified drug use (OR=4.368) and respiratory infections (OR=5.795) were independently associated with CHD diagnosis, followed by age (OR=0.680) and smoking (OR=1.476). The model showed excellent discrimination (AUC=0.867). Random forest analysis confirmed respiratory tract infections as the significant associated factor. Cost-effectiveness analysis identified the three-tier screening model as dominant, offering the lowest cost (¥2604) and highest health benefit (0.060 QALYs), with the favorable incremental cost-utility ratio. Single-stage diagnosis was the least cost-effective (¥15,400). Conclusion: The three-tier screening strategy, prioritizing children with maternal history of drug use or smoking exposure, younger age, and history of respiratory tract infections, shows a promising cost-effective approach for early CHD detection in high-altitude settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.